However, there is no clear consensus on whether anti-PD-1/PD-L1 antibodies or anti-PD-1/PD-L1 antibodies plus chemotherapy is more suitable for the patients with NSCLC expressing PD-L1 TPS ≥ 50%. Here, PDCD1 is linked to non-small cell lung carcinoma.